Karyopharm Therapeutics Inc. (KPTI) Stock

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is led by CEO Richard A. Paulson, employs 279 people, headquartered in US, publicly traded since 2013.

Karyopharm Therapeutics Inc. (KPTI) stock trades at $0.52 with a market capitalization of $11.74M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.02, reflecting a net loss over the last twelve months, a negative price-to-book of -0.04, reflecting negative shareholders' equity, price-to-sales of 0.07. Over the past 52 weeks the stock has ranged between $0.31 and $10.99, and currently trades 95.3% below its 52-week high.

On profitability, Karyopharm Therapeutics Inc. generates a return on equity (ROE) of 77.63% (not meaningful, as shareholders' equity is negative), return on capital employed of 359.36%, an operating margin of -62.33%, a net profit margin of -153.28%.

Karyopharm Therapeutics Inc. by the numbers, 2016–2025

Between 2016 and 2025 Karyopharm Therapeutics Inc. reported revenue of $0 rising to $146.0M. Compounded, revenue has grown 6.2% a year over five years, -2.4% over three, 0.7% over the last twelve months. Net profit fell to $-196.0M.

Operating margin went from -71903.9% in 2016 to -62.1% in 2025, a gain of 71841.8 percentage points. The most recent net margin is -153.28%. On a trailing twelve-month basis to Jun '26, revenue is $146.0M and net profit $-224.0M.

Borrowings stand at $234.0M, cash from operations was $-75.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged 267.7% over five years, and was 66.9% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Karyopharm Therapeutics Inc. (KPTI) — frequently asked questions